Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 1
1982 2
1983 1
1984 2
1985 3
1986 4
1987 5
1988 5
1989 5
1990 9
1991 4
1992 7
1993 6
1994 5
1995 7
1996 5
1997 3
1998 7
1999 3
2000 9
2001 8
2002 7
2003 8
2004 6
2005 5
2006 16
2007 11
2008 5
2009 3
2010 10
2011 9
2012 15
2013 8
2014 10
2015 7
2016 8
2017 6
2018 6
2019 12
2020 13
2021 13
2022 6
2023 13
2024 9
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

290 results

Results by year

Filters applied: . Clear all
Page 1
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R. Miyazaki I, et al. Among authors: ohkubo s. Nat Cancer. 2023 Sep;4(9):1345-1361. doi: 10.1038/s43018-023-00630-y. Epub 2023 Sep 21. Nat Cancer. 2023. PMID: 37743366 Free PMC article.
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.
Tsuge A, Watanabe S, Kawazoe A, Togashi Y, Itahashi K, Masuda M, Sai A, Takei S, Muraoka H, Ohkubo S, Sugiyama D, Yan Y, Fukuoka S, Doi T, Shitara K, Koyama S, Nishikawa H. Tsuge A, et al. Among authors: ohkubo s. Cancer Immunol Res. 2025 Feb 3;13(2):273-285. doi: 10.1158/2326-6066.CIR-24-0713. Cancer Immunol Res. 2025. PMID: 39602577
Trabeculectomy Tenon Advancement Technique May Reduce Bleb-Related Infections.
Mambo Y, Higashide T, Ohkubo S, Udagawa S, Yamashita Y, Tsuchiya S, Okayama M, Wajima R, Sugiyama K. Mambo Y, et al. Among authors: ohkubo s. J Glaucoma. 2023 Feb 1;32(2):107-116. doi: 10.1097/IJG.0000000000002126. Epub 2022 Sep 12. J Glaucoma. 2023. PMID: 36223327 Free PMC article.
Novel antitumor antibiotics, tetrocarcins.
Tomita F, Tamaoki T, Shirahata K, Kasai M, Morimoto M, Ohkubo S, Mineura K, Ishii S. Tomita F, et al. Among authors: ohkubo s. J Antibiot (Tokyo). 1980 Jun;33(6):668-70. doi: 10.7164/antibiotics.33.668. J Antibiot (Tokyo). 1980. PMID: 6893447 Free article. No abstract available.
Prevention of carcinogenesis and cancer metastasis by bovine lactoferrin.
Tsuda H, Fukamachi K, Xu J, Sekine K, Ohkubo S, Takasuka N, Iigo M. Tsuda H, et al. Among authors: ohkubo s. Proc Jpn Acad Ser B Phys Biol Sci. 2006 Nov;82(7):208-15. doi: 10.2183/pjab.82.208. Epub 2006 Nov 18. Proc Jpn Acad Ser B Phys Biol Sci. 2006. PMID: 25792784 Free PMC article. Review.
290 results